Radioimmunotherapy of Lymphoma: Bexxar and Zevalin

被引:90
|
作者
Goldsmith, Stanley J. [1 ]
机构
[1] New York Presbyterian Hosp, Weill Cornell Med Ctr, Div Nucl Med, Weill Cornell Coll Med, New York, NY 10065 USA
关键词
NON-HODGKINS-LYMPHOMA; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; I-131; TOSITUMOMAB; LOW-GRADE; THERAPY; ANTIBODY; SUBSEQUENT;
D O I
10.1053/j.semnuclmed.2009.11.002
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Radioimmunotherapy is a form of targeted radionuclide therapy that uses a monoclonal antibody to deliver localized radiation. It is most appropriate for treatment of multiple tumor sites that cannot be readily excised surgically or irradiated using external beam radiation or brachytherapy. At present, 2 products, Bexxar (I-131-tositumomab and unlabeled tositumomab, GlaxoSmithKline, Triangle Park, NC) and Zevalin (Y-90-ibritumomab tiuxetan and unlabeled rituximab, Spectrum Pharmaceuticals, Irvine, CA and Cell Therapeutics, Seattle, WA) are approved for treatment of non-Hodgkin's lymphoma in certain clinical situations in the United States and Canada. Zevalin is available also in Europe, and there are plans to make both agents more widely available. The therapeutic dose to be used depends upon a number of patient-specific variables. Both regimen achieve a complete response or partial response in approximately 3 of 4 patients, with a duration of remission lasting many years in some cases. This article reviews the basis for dose selection, the nuclear medicine procedures involved, the results obtained to date, and issues related to patient and staff safety. Semin Nucl Med 40:122-135 (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:122 / 135
页数:14
相关论文
共 50 条
  • [1] Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
    Sachpekidis, Christos
    Jackson, David B.
    Soldatos, Theodoros G.
    PHARMACEUTICALS, 2019, 12 (04)
  • [2] Radioimmunotherapy with Zevalin in marginal-zone lymphoma
    Grana, C. M.
    Vanazzi, A.
    Bodei, L.
    Baio, S. M.
    Bartolomei, M.
    Martinelli, G.
    Paganelli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S352 - S352
  • [3] Zevalin™ radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma
    White, CA
    Wiseman, GA
    Witzig, TE
    Gordon, LI
    Leigh, B
    Grillo-López, AJ
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S57 - S57
  • [4] Radioimmunotherapy with 90Y-Zevalin in mantle cell lymphoma patients.
    Sowa-Staszczak, A.
    Hubalewska-Dydejczyk, A.
    Jurczak, W.
    Huszno, B.
    Giza, A.
    Wegrzyn, J.
    Skotnicki, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S195 - S195
  • [5] Zevalin™ radioimmunotherapy of Rituximab-refractory follicular non-Hodgkin's lymphoma
    Witzig, TE
    White, CA
    Flinn, IW
    Gordon, L
    Emmanouilides, C
    Cripe, LD
    Saleh, M
    Czuczman, MS
    Wiseman, GA
    Spies, S
    Silverman, DH
    Burt, RW
    Olejnik, T
    Grillo-López, AJ
    BLOOD, 2000, 96 (11) : 507A - 507A
  • [6] Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma
    Wiseman, GA
    Leigh, B
    Erwin, WD
    Lamonica, D
    Kornmehl, E
    Spies, SM
    Silverman, DHS
    Witzig, TE
    Sparks, RB
    White, CA
    CANCER, 2002, 94 (04) : 1349 - 1357
  • [7] Efficacy of patient release criteria & instructions for outpatient radioimmunotherapy of lymphoma with bexxar (131I-tositumomab).
    Gobar, LS
    Rutar, F
    Vose, JA
    Augustine, S
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 269P - +
  • [8] Multicenter experience with the Zevalin radiolabeling kit for radioimmunotherapy of non-Hodgkin's lymphoma.
    Wiseman, GA
    Gordon, LI
    Leigh, BR
    Witzig, TE
    Spies, S
    Emmanouilidies, C
    Czuczman, MS
    Podoloff, DA
    Wakefield, M
    Grillo-López, AJ
    White, CA
    BLOOD, 2000, 96 (11) : 251B - 251B
  • [9] Tumor dosimetry results for Zevalin™ radioimmunotherapy.
    Wiseman, GA
    Leigh, BR
    Erwin, WD
    Podoloff, DA
    Lamonica, DM
    Royal, HD
    Parker, JA
    Dunn, WL
    Spies, SM
    White, CA
    BLOOD, 2001, 98 (11) : 606A - 606A
  • [10] Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with Zevalin™ for non-Hodgkin lymphoma.
    Ansell, SM
    Ristow, KM
    Habermann, TM
    Wiseman, GA
    Witzig, TE
    BLOOD, 2001, 98 (11) : 604A - 605A